دورية أكاديمية
Invasive fungal infection following venetoclax and posaconazole co-administration.
| العنوان: | Invasive fungal infection following venetoclax and posaconazole co-administration. |
|---|---|
| المؤلفون: | Reynolds G; Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia., Urbancic KF; Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.; Department of Pharmacy, Austin Health, Heidelberg, Victoria, Australia.; Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia., Fong CY; Department of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia., Trubiano JA; Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia.; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.; Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia. |
| المصدر: | British journal of haematology [Br J Haematol] 2023 Nov; Vol. 203 (4), pp. 593-598. Date of Electronic Publication: 2023 Sep 20. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Wiley-Blackwell Original Publication: Oxford : Blackwell Scientific Publications |
| مواضيع طبية MeSH: | Leukemia, Myeloid, Acute*/drug therapy , Invasive Fungal Infections*/drug therapy , Invasive Fungal Infections*/prevention & control, Humans ; Antifungal Agents/therapeutic use ; Retrospective Studies |
| مستخلص: | The co-administration of venetoclax, a BCL-2 inhibitor, with a mould-active azole, such a posaconazole, has potential to both prevent invasive fungal infection (IFI) and reduce the required treatment dose, and cost, of venetoclax. Posaconazole drug-level monitoring is critical to ensuring adequate mould prophylaxis. A retrospective audit of 99 patients at a tertiary cancer centre, with myeloid malignancies co-prescribed venetoclax and posaconazole between January 2018 and April 2022, was undertaken to evaluate the adequacy of posaconazole prescribing and the rate of breakthrough IFI. Seventy-six patients (77%) had at least one posaconazole level measured in the study period, with 37% requiring a dose adjustment based on steady-state trough levels. Breakthrough IFI occurred in 4% of patients, typically within 1 month of commencing anti-mould prophylaxis. Close monitoring of posaconazole levels in venetoclax-treated patients, particularly in the early, outpatient setting, is critical. (© 2023 British Society for Haematology and John Wiley & Sons Ltd.) |
| التعليقات: | Comment in: Br J Haematol. 2023 Nov;203(4):504-506. (PMID: 37803499) |
| References: | Pollyea DA. Venetoclax in AML: where we are and where we are headed. Clin Lymphoma Myeloma Leuk. 2020;20(Suppl 1):S25-S26. Reinwald M, Silva JT, Mueller NJ, Fortún J, Garzoni C, de Fijter JW, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors). Clin Microbiol Infect. 2018;24:S53-S70. Aldoss I, Dadwal S, Zhang J, Tegtmeier B, Mei M, Arslan S, et al. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Adv. 2019;3(23):4043-4049. Shimony S, Stone RM, Stahl M. Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes. Curr Opin Hematol. 2022;29(2):63-73. Chen EC, Liu Y, Harris CE, Winer ES, Wadleigh M, Lane AA, et al. Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax. Leuk Lymphoma. 2022;63:1-8. Douglas AP, Smibert OC, Bajel A, Halliday CL, Lavee O, McMullan B, et al. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. Intern Med J. 2021;51(S7):143-176. Maertens JA, Girmenia C, Brüggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221-3230. Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin Infect Dis. 2019;71(6):1367-1376. Märtson A-G, Veringa A, van den Heuvel ER, Bakker M, Touw DJ, van der Werf TS, et al. Posaconazole therapeutic drug monitoring in clinical practice and longitudinal analysis of the effect of routine laboratory measurements on posaconazole concentrations. Mycoses. 2019;62(8):698-705. Kang K-W, Lee B-H, Jeon MJ, Yu ES, Sik Kim D, Lee SR, et al. Efficacy of posaconazole prophylaxis in acute myeloid leukemia and myelodysplastic syndrome patients treated with hypomethylating agents. Ther Adv Hematol. 2020;11:2040620720966882. Chen L, Wang Y, Zhang T, Li Y, Meng T, Liu L, et al. Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis. BMC Infect Dis. 2018;18(1):155. Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas R-O, Ysebaert L, et al. Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the Ro-CHOP phase III study (conducted by LYSA). J Clin Oncol. 2022;40(3):242-251. Hall VG, Tang K, Kumar D, Rotstein C, Chow S, Chan SM, et al. Breakthrough invasive fungal infection after coadministration of venetoclax and voriconazole. Open Forum Infect Dis. 2023;10:ofad134. Shuman K, Hunt RG, Hibino M, Stone T, Dralle S, Manuel M, et al. Incidence of breakthrough fungal infections in acute myeloid leukemia patients receiving low intensity therapy in the upfront and relapsed/refractory setting. Blood. 2021;138:3372. Li Z, Wang J, Ge SS, Qiu QC, Du JH, Shan SS, et al. Combination of venetoclax and midostaurin efficiently suppressed relapsed t(8;21)acute myeloid leukemia with mutant KIT after failure of venetoclax plus azacitidine treatment. Front Oncol. 2022;12:841276. Krapfl A, McLeod C, Myers R, Venugopal P, Seddon A. Venetoclax ramp-up with concurrent voriconazole in a patient with chronic lymphocytic leukemia. J Oncol Pharm Pract. 2022;28:1898-1901. Chua CC, Roberts AW, Reynolds J, Fong CY, Ting SB, Salmon JM, et al. Chemotherapy and venetoclax in elderly acute myeloid leukemia trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy. J Clin Oncol. 2020;38(30):3506-3517. Batchelor R, Thomas C, Gardiner BJ, Lee SJ, Fleming S, Wei A, et al. When azoles cannot be used: the clinical effectiveness of intermittent liposomal amphotericin prophylaxis in hematology patients. Open Forum Infect Dis. 2021;8(7):ofab113. Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, et al. Management of venetoclax-posaconazole interaction in acute myeloid leukemia patients: evaluation of dose adjustments. Clin Ther. 2017;39(2):359-367. |
| فهرسة مساهمة: | Keywords: BCL-2; MDS; antifungal; fungal infection; infection |
| المشرفين على المادة: | 6TK1G07BHZ (posaconazole) 0 (Antifungal Agents) N54AIC43PW (venetoclax) |
| تواريخ الأحداث: | Date Created: 20230921 Date Completed: 20231115 Latest Revision: 20231124 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1111/bjh.19116 |
| PMID: | 37731068 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1365-2141 |
|---|---|
| DOI: | 10.1111/bjh.19116 |